Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.62 |
| ▸ | BRAF | P15056 | 14/20 | 0.54 |
| ▸ | FYN | P06241 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056831 | 0.93 | CSF1R (0.60) | CSF1RBRAFFYN | |
| SCHEMBL12056878 | 0.93 | CSF1R (0.60) | CSF1RBRAFFYN | |
| SCHEMBL18286642 | 0.93 | CSF1R (0.60) | CSF1RBRAFFYN | |
| SCHEMBL19447189 | 0.89 | CSF1R (0.57) | CSF1RBRAFFYN | |
| SCHEMBL13340175 | 0.88 | CSF1R (0.67) | CSF1RBRAF | |
| SCHEMBL12065367 | 0.88 | CSF1R (0.81) | CSF1RBRAF | |
| SCHEMBL13340176 | 0.88 | CSF1R (0.67) | CSF1RBRAF | |
| SCHEMBL13340183 | 0.87 | CSF1R (0.68) | CSF1RBRAF | |
| SCHEMBL12065053 | 0.86 | CSF1R (0.57) | CSF1RBRAFFYN | |
| SCHEMBL12064807 | 0.86 | CCNT1 (0.54) | CSF1RBRAFFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | CSF1R 2097/4885BRAF 250/4885FYN 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.